469 results on '"Hiley C"'
Search Results
2. Changes in the Management of Patients having Radical Radiotherapy for Lung Cancer during the First Wave of the COVID-19 Pandemic in the UK
3. 77P Experience pooling control arms within a complex phase I drug-radiotherapy (RT) platform trial
4. Neutrophil–Lymphocyte Ratio and Absolute Lymphocyte Count as Prognostic Markers in Patients Treated with Curative-intent Radiotherapy for Non-small Cell Lung Cancer
5. Predicting the Risk of Disease Recurrence and Death Following Curative-intent Radiotherapy for Non-small Cell Lung Cancer: The Development and Validation of Two Scoring Systems From a Large Multicentre UK Cohort
6. Antiferromagnetism at T > 500 K in the Layered Hexagonal Ruthenate SrRu2O6
7. P2.01-04 An Update on the CONCORDE study: A Phase Ib Platform Study of Novel Agents in Combination With Conventional Radiotherapy in NSCLC
8. Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters
9. MO-0467 Impact of the COVID-19 pandemic on patient outcomes after curative-intent radiotherapy in the UK
10. PO-1943 A comparison of proton and photon radiotherapy for treatment of malignant pleural mesothelioma
11. Endothelial Nitric Oxide Suppresses Action-Potential-Like Transient Spikes and Vasospasm in Small Resistance Arteries
12. 28MO Adapting the Time-to-Event Continual Reassessment Method (TiTE-CRM) to include consolidation immunotherapy in a phase I drug-radiotherapy platform trial
13. EP05.01-007 CONCORDE - A Phase Ib Platform Study of Novel Agents in COmbinatioN with COnventional RaDiothErapy in Non-small Cell Lung Cancer (NSCLC)
14. EP08.03-005 HALT - Targeted Therapy with or without Dose-Intensified Radiotherapy in Oligo-Progressive Disease in Oncogene Addicted Lung Tumours
15. 28P Identification of convergent gene repression mechanisms through integrative genomic and DNA methylation analysis in NSCLC
16. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
17. Current applications and future development of magnetic resonance fingerprinting in diagnosis, characterization, and response monitoring in cancer
18. A Mitochondria-Targeted S-Nitrosothiol Modulates Respiration, Nitrosates Thiols, and Protects against Ischemia-Reperfusion Injury
19. Mechanisms of vasorelaxation induced by the cannabidiol analogue compound O-1602 in the rat small mesenteric artery
20. Development and Validation of a Sponge Model for Quantitative Studies on Angiogenesis
21. PO-1199 Cardiac disease and tumour below T7 confer poorer prognosis following radical radiotherapy for NSCLC
22. OC-0633 Cardiac substructure avoidance in lung cancer using photon vs proton radiotherapy: A planning study
23. PD-0875 Novel Classification and Longitudinal Analysis of Radiation-Induced Lung Parenchyma Damage
24. PH-0274 NLR & ALC as prognostic markers in patients treated with curative intent radiotherapy for NSCLC
25. OC-0533 Two Centre Feasibility study of single fraction lung stereotactic ablative radiotherapy (SABR)
26. LBA72 DARWIN II: Deciphering anti-tumour response and resistance to immunotherapy with intratumour heterogeneity in NSCLC
27. 1323MO Immune evasion across space and time in patients with lung cancer enrolled in the PEACE autopsy study
28. The GPR55 agonist lysophosphatidylinositol relaxes rat mesenteric resistance artery and induces Ca2+ release in rat mesenteric artery endothelial cells
29. Using DNA sequencing data to quantify T cell fraction and therapy response
30. Lister strain vaccinia virus, a potential therapeutic vector targeting hypoxic tumours
31. Reduced Fractionation in Lung Cancer Patients Treated with Curative-intent Radiotherapy during the COVID-19 Pandemic
32. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer
33. Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials
34. Stereotactic ablative body radiotherapy (SABR) combined with Immunotherapy (L19-IL2) in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial
35. In silico patent searching reveals a new cannabinoid receptor
36. Corrigendum to “73 - Five years of stereotactic radiotherapy for early lung cancer: Biopsy rates, outcomes and implications” [Lung Cancer, 139, 1, (January 2020) Page S31]
37. SP-0016: The use of genomics in radiation oncology
38. Mechanisms of vasorelaxation induced by oleoylethanolamide in the rat small mesenteric artery
39. Chapter 5 Is GPR55 an Anandamide Receptor?
40. Is there variation in health care for children and young people with cerebral palsy across the North of England? An audit of clinical practice
41. Neutrophil lymphocyte ratio as a prognostic marker in patients treated with curative intent radiotherapy for non-small cell lung cancer
42. Five years of stereotactic radiotherapy for early lung cancer: biopsy rates, outcomes and implications
43. The role of NOTCH2NLB in NSCLC and resistance to ionising radiation
44. P2.01-25 TOURIST: Thoracic Umbrella Radiotherapy Study in Stage IV NSCLC: A Phase III Randomized Trial in Development
45. P1.04-43 PD-RAD: A Translational Study Investigating PD-L1 Expression After Radiotherapy for Non-Small Cell Lung Cancer - Trial in Progress
46. P2.01-08 Clinical Trial in Progress: CONCORDE - A Phase 1B Study of Novel Agents in Combination with Conventional Radiotherapy in NSCLC
47. Studies on the Muscarinic Receptor
48. Quantification of the repair process involved in the repair of a cell monolayer using an in vitro model of mechanical injury
49. Vascular pharmacology of a novel cannabinoid-like compound, 3-(5-dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1-methyl-ethyl)benzamide (VSN16) in the rat
50. GPR55 and the vascular receptors for cannabinoids
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.